Cargando…

Response to Crudele et al. Commentary on Gudin et al. “Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties”

Detalles Bibliográficos
Autores principales:	Gudin, Jeff, Kopecky, Ernest A., Fleming, Alison B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431382/ https://www.ncbi.nlm.nih.gov/pubmed/28074029 http://dx.doi.org/10.1093/pm/pnw279

Ejemplares similares

In response to Gudin et al. — Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties
por: Crudele, Nancy T., et al.
Publicado: (2017)

Response to Crudele et al. Commentary on Mayock et al. “In Vitro Drug Release after Crushing: Evaluation of Xtampza(®) ER and Other ER Opioid Formulations”
por: Fleming, Alison B., et al.
Publicado: (2018)

Oxycodone DETERx(®): A Novel Abuse-Deterrent, Extended-Release Analgesic Option for the Treatment of Patients with Chronic Pain
por: Gudin, Jeff
Publicado: (2016)

A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone
por: Webster, Lynn R., et al.
Publicado: (2016)

Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study
por: Webster, Lynn R., et al.
Publicado: (2019)

Oxycodone hydrochloride immediate-release analgesic for managing severe pain: abuse-deterrent formulations
por: Kibbe, AH, et al.
Publicado: (2018)

Analgesic efficacy, safety, and tolerability of a long-acting abuse-deterrent formulation of oxycodone for moderate-to-severe chronic low back pain in subjects successfully switched from immediate-release oxycodone
por: Markman, John, et al.
Publicado: (2018)

Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program
por: L. Keast, Shellie, et al.
Publicado: (2016)

Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation†
por: Sessler, Nelson E, et al.
Publicado: (2014)

A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population
por: Jewell, Jennifer, et al.
Publicado: (2023)

Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product
por: Pergolizzi, Joseph V, et al.
Publicado: (2018)

Correction to: A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population
por: Jewell, Jennifer, et al.
Publicado: (2023)

Oral Human Abuse Potential of Oxycodone DETERx(®) (Xtampza(®) ER)
por: Kopecky, Ernest A., et al.
Publicado: (2016)

Oxycodone/Naloxone: Role in Chronic Pain Management, Opioid-Induced Constipation, and Abuse Deterrence
por: DePriest, Anne Z., et al.
Publicado: (2014)

Commentary on Simon et al
por: Pascoal, Patrícia M.
Publicado: (2022)

Commentary on Simon et al
por: Shindel, Alan W.
Publicado: (2022)

Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics
por: Coplan, Paul M, et al.
Publicado: (2013)

Response to commentary by Skinner et al. on Regression to the Mean (RTM) in Burke et al.
por: Burke, Rachel M, et al.
Publicado: (2015)

Dancing with Deterrents: Understanding the Role of Abuse‐Deterrent Opioid Formulations and Naloxone in Managing Cancer Pain
por: Mitchell, Megan T.
Publicado: (2019)

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation
por: Webster, Lynn R, et al.
Publicado: (2019)

Hypothermia plus Erythropoietin for neonatal neuroprotection? Commentary on Fan et al. and Fang et al.
por: Juul, Sandra E.
Publicado: (2013)

Response to the Commentary from Bevelacqua et al.
por: Limoli, Charles L., et al.
Publicado: (2020)

Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users
por: Harris, Stephen C, et al.
Publicado: (2014)

The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute Pain
por: Pergolizzi, Joseph V., et al.
Publicado: (2015)

Cryobiopsy Compared with Surgical Lung Biopsy in ILD: Reply to Maldonado et al., Froidure et al., Bendstrup et al., Agarwal et al., Richeldi et al., Rajchgot et al., and Quadrelli et al.
por: Romagnoli, Micaela, et al.
Publicado: (2019)

Can abuse deterrent formulations make a difference? Expectation and speculation
por: Budman, Simon H, et al.
Publicado: (2009)

Non-exclusive exclusion (Commentary on Capello et al.)
por: Rodriguez-Gil, Diego, et al.
Publicado: (2009)

AAV shuffles to the liver: commentary on Lisowski et al.
por: Schaffer, David V
Publicado: (2014)

Pragmatics for infants: commentary on Wenzel et al. (2020)
por: Rubio-Fernandez, Paula, et al.
Publicado: (2021)

Mitigation of IV Abuse Through the Use of Abuse‐Deterrent Opioid Formulations: An Overview of Current Technologies
por: Rauck, Richard L.
Publicado: (2019)

Reply by Gattinoni et al. to Hedenstierna et al., to Maley et al., to Fowler et al., to Bhatia and Mohammed, to Bos, to Koumbourlis and Motoyama, and to Haouzi et al.
por: Gattinoni, Luciano, et al.
Publicado: (2020)

The need for genetically‐informative designs in developmental science: Commentary on Gustavson et al. (2021) and Myers et al. (2021)
por: Taylor, Mark J.
Publicado: (2021)

Cost of opioid medication abuse with and without tampering in the USA
por: Vietri, Jeffrey, et al.
Publicado: (2018)

Reply to Cottin et al., to Johannson et al., to Scholand and Wells, and to Crowley et al.
por: Raghu, Ganesh, et al.
Publicado: (2022)

Response to Sadek et al. and Kotlikoff et al.
por: Andersen, Ditte Caroline, et al.
Publicado: (2014)

Reply to Lescoat et al. and to Khamis et al.
por: Adegunsoye, Ayodeji, et al.
Publicado: (2019)

Reply to Chase et al. and to Milner et al.
por: Mittel, Aaron M., et al.
Publicado: (2020)

Reply by Xu et al. to Haouzi et al.
por: Xu, Yonghao, et al.
Publicado: (2020)

Reply by Pan et al. to Haouzi et al.
por: Pan, Chun, et al.
Publicado: (2020)

Reply to Topeli et al. and to Akinosoglou et al.
por: Azevedo, Luciano C. P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_epkk4fgsn3riod92piit68ge33